Domestic Ophthalmic Therapeutics Sector Raises Over RMB 3 Billion in a Month, Accelerating Localization Substitution

　　【Pharmaceutical Network Industry DynamicsRecently, many enterprises in China's pharmaceuticals and health sector have secured financing, including some in the ophthalmology field such as Tianchen Biotech and Microclear Medical. The funds raised will mainly be used to enhance R&D, expand product lines, and accelerate overseas market expansion.
 

News on April 16, Intalight (Henan) Technology Co., Ltd. (hereinafter referred to as "Intalight Saiwei") announced that the company has recently completed a D-round financing of over 100 million yuan led by Haitong Kaiyuan. The funds will mainly be used to increase R&D investment, expand product lines, and accelerate the overseas market layout. It is worth mentioning that in 2023, Intalight Saiwei received over 300 million yuan in C-round financing and tens of millions of yuan in strategic financing from Huaxia Ophthalmology, with a total financing amount exceeding 400 million yuan. Investors included investment institutions such as Guoshou Equity, Qianhai Ark, Chen De Capital, Shenzhen Capital Group, Zhongjin Huirong, Lingang Blue Bay, as well as two major ophthalmic industry investors, Aier Medical and Huaxia Ophthalmology.
 

On March 27, Tianchen Bio announced the completion of a 100 million RMB A+ round of financing, with CMB International as the investor. The company specializes in the research, development, production, and sales of Class III ophthalmic medical devices. Equipped with expertise in material science, optics, and ophthalmic clinical teams, it develops innovative medical devices to address unmet clinical needs in ophthalmology, with products covering both active and passive devices. At the end of October 2023, the company had just announced the completion of an over 100 million RMB B1 round of financing participated by Huzhou Youcheng, Fuhai Jiaozichuangtou, Shan Zheng Innovation, Changshu Wuyue Angel Venture Capital, and Hefei Hongda. The funds from this round will mainly be used for the clinical advancement and industrialization preparation of the company’s innovative drug projects, supporting the internationalization process of the projects.
 

According to Tianyancha information on March 26, Microclear Medical completed a D-round financing of 100 million RMB, with the investor being the China State-owned Capital Venture Investment Fund. The company is a research and production enterprise specializing in high-end ophthalmic imaging and intelligent devices, focusing on the ophthalmology and optometry niche markets. Its core products include confocal laser fundus angiography systems, fundus cameras, and handheld digital slit lamps. After completing this round of financing, the company will strengthen the global position of its core product, the "ultra-wide-angle confocal laser camera," and accelerate new product R&D iteration, market promotion, and the construction of a high-level talent team.
 

Experts in the industry indicate that the eyes are vital organs of the human body, and eye health is increasingly valued by modern people. Due to the intricate and complex structure of the eyes, advanced ophthalmic medical devices are crucial for achieving precise diagnosis and treatment in ophthalmology. High-end ophthalmic equipment not only enables early detection and helps doctors manage potential eye diseases, reducing the burden of ocular diseases and the risk of blindness, but also improves diagnostic accuracy, lowers surgical risks, enhances the safety and success rates of surgeries, and significantly improves treatment outcomes.
 

High-end ophthalmic medical equipment covers ophthalmic surgeryMicroscopeOphthalmic Optical Coherence Tomography (OCT), ophthalmic optical biometer, ultra-wide-field fundus camera, phacoemulsification and vitrectomy integrated machine, and femtosecond laser, among other high-value, high-tech ophthalmic diagnostic and treatment devices, all play important roles in the diagnosis and treatment of ophthalmic diseases.
 

In recent years, driven by favorable policies, the development of China's ophthalmic medical device industry has been rapid, with a continuous emergence of high-end domestically produced ophthalmic medical devices. As capital investment increases, the process of domestic substitution is expected to accelerate, and in the future, domestic alternatives are hoped to be realized in more areas of high-end ophthalmic medical devices, meeting the needs of more patients.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.